These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28254519)

  • 1. Assessment of the structure of pegylated-recombinant protein therapeutics by the NMR fingerprint assay.
    Hodgson DJ; Aubin Y
    J Pharm Biomed Anal; 2017 May; 138():351-356. PubMed ID: 28254519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers.
    Dhalluin C; Ross A; Leuthold LA; Foser S; Gsell B; Müller F; Senn H
    Bioconjug Chem; 2005; 16(3):504-17. PubMed ID: 15898716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring Effects of Excipients, Formulation Parameters and Mutations on the High Order Structure of Filgrastim by NMR.
    Aubin Y; Hodgson DJ; Thach WB; Gingras G; Sauvé S
    Pharm Res; 2015 Oct; 32(10):3365-75. PubMed ID: 26043856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
    Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recombinant granulocyte-colony stimulating factor (filgrastim): optimization of conjugation with polyethylene glycol].
    Puchkov IA; Kononova NV; Bobruskin AI; Bairamashvili DI; Mart'ianov VA; Shuster AM
    Bioorg Khim; 2012; 38(5):545-54. PubMed ID: 23342488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of a pegylated interferon-alpha2a product by a customised and validated reverse phase-high performance liquid chromatography method.
    El Ghazaly M; Meager A; Zikry H; Ebaed M; Shaker S; Mueller F; Rohde J
    J Pharm Biomed Anal; 2013 Oct; 84():48-52. PubMed ID: 23797040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim.
    Kuehne H; Davis JM; Merewether L; McQueen M; Valentine E; Young G; Andrews BT; Diaz D; Miller KJ
    Drugs R D; 2024 Jun; 24(2):285-301. PubMed ID: 38958918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism.
    Elsadek NE; Emam SE; Abu Lila AS; Shimizu T; Ando H; Ishima Y; Ishida T
    Biol Pharm Bull; 2020; 43(9):1393-1397. PubMed ID: 32879214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: Production and physicochemical characterization.
    Scaramuzza S; Tonon G; Olianas A; Messana I; Schrepfer R; Orsini G; Caliceti P
    J Control Release; 2012 Dec; 164(3):355-63. PubMed ID: 22735238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2.
    Dhalluin C; Ross A; Huber W; Gerber P; Brugger D; Gsell B; Senn H
    Bioconjug Chem; 2005; 16(3):518-27. PubMed ID: 15898717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the major positional isomer of pegylated interferon alpha-2b.
    Wang YS; Youngster S; Bausch J; Zhang R; McNemar C; Wyss DF
    Biochemistry; 2000 Sep; 39(35):10634-40. PubMed ID: 10978146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylation: engineering improved pharmaceuticals for enhanced therapy.
    Molineux G
    Cancer Treat Rev; 2002 Apr; 28 Suppl A():13-6. PubMed ID: 12173407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim.
    Hong J; Lee B; Kang K; Lee SH; Ryu J; Jung G; Oh J; Jo EC; Kim CW
    Biologicals; 2018 Jan; 51():54-61. PubMed ID: 29107446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of next generation of therapeutic IFN-α2b via genetic code expansion.
    Zhang B; Xu H; Chen J; Zheng Y; Wu Y; Si L; Wu L; Zhang C; Xia G; Zhang L; Zhou D
    Acta Biomater; 2015 Jun; 19():100-11. PubMed ID: 25769229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the self-association of human interferon-α2b, albinterferon-α2b, and pegasys.
    Li Y; Stafford WF; Hesselberg M; Hayes D; Wu Z; Byrne M
    J Pharm Sci; 2012 Jan; 101(1):68-80. PubMed ID: 21975852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.
    Barril G; Quiroga JA; Sanz P; Rodrìguez-Salvanés F; Selgas R; Carreño V
    Aliment Pharmacol Ther; 2004 Jul; 20(1):37-44. PubMed ID: 15225169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM; Chan LJ; Ryan GM; Porter CJ; Kaminskas LM
    J Pharm Sci; 2015 Apr; 104(4):1421-30. PubMed ID: 25631360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.